Literature DB >> 17418155

Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women.

David B Seifer1, Elizabeth T Golub, Geralyn Lambert-Messerlian, Gayle Springer, Susan Holman, Michael Moxley, Helen Cejtin, Niyati Nathwani, Kathryn Anastos, Howard Minkoff, Ruth M Greenblatt.   

Abstract

OBJECTIVE: To compare Müllerian inhibiting substance (MIS) levels in serum obtained during the early follicular phase to those obtained randomly during the menstrual cycle. To determine whether HIV infection influences early follicular MIS levels, an early marker of ovarian aging.
DESIGN: A cross-sectional study.
SETTING: Women's Interagency HIV Study, a multicenter prospective study. PATIENT(S): Serum samples obtained from 263 (187 HIV infected and 76 uninfected) participants of the Women's Interagency HIV Study who reported menstrual bleeding during the preceding 6 months and who were not taking exogenous hormones. INTERVENTION(S): Early follicular (cycle days 2-5) MIS samples were compared with serum samples that had been obtained without regard to menstrual cycle phase. Comparison samples were obtained within 6 weeks before or within 3 to 6 months after the early follicular samples. Early follicular FSH, E(2), inhibin B, and MIS levels were also compared between the HIV infected and uninfected women. MAIN OUTCOME MEASURE(S): Correlation between early follicular MIS and prior and subsequent samples. Comparison of serum markers of ovarian reserve between HIV positive and negative women. RESULT(S): The MIS values from early follicular and other random cycle phases were highly correlated with each other (r > 0.93). In multivariate analysis, increased age and FSH level and lower inhibin B levels were associated with lower MIS level; MIS values did not vary by HIV serostatus. CONCLUSION(S): Without regard to cycle phase, MIS was similar during early follicular phase and highly correlated with early follicular FSH and inhibin B in women with and without HIV. Measurement of serum MIS offers a simplified method of determining ovarian reserve using specimens obtained without menstrual phase timing. Furthermore, using biologic measures of reproductive aging, we found no evidence that HIV infection influences ovarian aging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418155      PMCID: PMC2682326          DOI: 10.1016/j.fertnstert.2007.01.122

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  33 in total

1.  Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve.

Authors:  I A J van Rooij; F J M Broekmans; E R te Velde; B C J M Fauser; L F J M M Bancsi; F H de Jong; A P N Themmen
Journal:  Hum Reprod       Date:  2002-12       Impact factor: 6.918

2.  Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.

Authors:  Renato Fanchin; Luca Maria Schonäuer; Claudia Righini; Jean Guibourdenche; René Frydman; Joëlle Taieb
Journal:  Hum Reprod       Date:  2003-02       Impact factor: 6.918

3.  Limitations of follicle-stimulating hormone in assessing menopause status: findings from the National Health and Nutrition Examination Survey (NHANES 1999-2000)*.

Authors:  Janet B Henrich; Jeffery P Hughes; Steven C Kaufman; Debra J Brody; Lester R Curtin
Journal:  Menopause       Date:  2006 Mar-Apr       Impact factor: 2.953

4.  Antimüllerian hormone serum levels: a putative marker for ovarian aging.

Authors:  Annemarie de Vet; Joop S E Laven; Frank H de Jong; Axel P N Themmen; Bart C J M Fauser
Journal:  Fertil Steril       Date:  2002-02       Impact factor: 7.329

5.  Effect of HIV infection on menstrual cycle length.

Authors:  S D Harlow; P Schuman; M Cohen; S E Ohmit; S Cu-Uvin; X Lin; K Anastos; D Burns; R Greenblatt; H Minkoff; L Muderspach; A Rompalo; D Warren; M A Young; R S Klein
Journal:  J Acquir Immune Defic Syndr       Date:  2000-05-01       Impact factor: 3.731

6.  Serum müllerian-inhibiting substance levels during normal menstrual cycles.

Authors:  C L Cook; Y Siow; S Taylor; M E Fallat
Journal:  Fertil Steril       Date:  2000-04       Impact factor: 7.329

7.  Early follicular antimüllerian hormone as an indicator of ovarian reserve.

Authors:  Cem Fiçicioglu; Tayfun Kutlu; Elif Baglam; Zeynep Bakacak
Journal:  Fertil Steril       Date:  2006-03       Impact factor: 7.329

8.  Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction.

Authors:  Helen E Cejtin; Ann Kalinowski; Peter Bacchetti; Robert N Taylor; D Heather Watts; Seijeoung Kim; L Stewart Massad; Susan Preston-Martin; Kathryn Anastos; Michael Moxley; Howard L Minkoff
Journal:  Obstet Gynecol       Date:  2006-12       Impact factor: 7.661

9.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

Authors:  David B Seifer; David T MacLaughlin; Benjamin P Christian; Bo Feng; Robert M Shelden
Journal:  Fertil Steril       Date:  2002-03       Impact factor: 7.329

10.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.

Authors:  A La Marca; S Giulini; A Tirelli; E Bertucci; T Marsella; S Xella; A Volpe
Journal:  Hum Reprod       Date:  2006-10-27       Impact factor: 6.918

View more
  14 in total

1.  Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal women.

Authors:  Muhammad Faisal Aslam; Zaher O Merhi; Safaa Ahmed; Oumar Kuzbari; David B Seifer; Howard Minkoff
Journal:  Fertil Steril       Date:  2011-04       Impact factor: 7.329

Review 2.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

3.  Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women.

Authors:  Rebecca Scherzer; Peter Bacchetti; Geralyn Messerlian; Johanna Goderre; Pauline M Maki; David B Seifer; Kathryn Anastos; Roksana Karim; Ruth M Greenblatt
Journal:  Am J Reprod Immunol       Date:  2014-10-23       Impact factor: 3.886

Review 4.  Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.

Authors:  Vitaly A Kushnir; William Lewis
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

Review 5.  Cardiovascular disease risk among women living with HIV in North America and Europe.

Authors:  Lauren Stone; Sara E Looby; Markella V Zanni
Journal:  Curr Opin HIV AIDS       Date:  2017-11       Impact factor: 4.283

Review 6.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

Review 7.  Gonadal function and reproductive health in women with human immunodeficiency virus infection.

Authors:  Swaytha Yalamanchi; Adrian Dobs; Ruth M Greenblatt
Journal:  Endocrinol Metab Clin North Am       Date:  2014-09       Impact factor: 4.741

8.  Variations in serum müllerian inhibiting substance between white, black, and Hispanic women.

Authors:  David B Seifer; Elizabeth T Golub; Geralyn Lambert-Messerlian; Lorie Benning; Kathryn Anastos; D Heather Watts; Mardge H Cohen; Roksana Karim; Mary A Young; Howard Minkoff; Ruth M Greenblatt
Journal:  Fertil Steril       Date:  2008-10-18       Impact factor: 7.329

9.  The Association Between HIV Status, Estradiol, and Sex Hormone Binding Globulin Among Premenopausal Women in the Women's Interagency HIV Study.

Authors:  Sally B Coburn; Jodie Dionne-Odom; Maria L Alcaide; Caitlin A Moran; Lisa Rahangdale; Elizabeth T Golub; Leslie Stewart Massad; Dominika Seidman; Katherine G Michel; Howard Minkoff; Kerry Murphy; Todd T Brown; Kala Visvanathan; Bryan Lau; Keri N Althoff
Journal:  J Womens Health (Larchmt)       Date:  2022-01-17       Impact factor: 2.681

10.  Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial.

Authors:  Markella V Zanni; Judith S Currier; Amy Kantor; Laura Smeaton; Corinne Rivard; Jana Taron; Tricia H Burdo; Sharlaa Badal-Faesen; Umesh G Lalloo; Jorge A Pinto; Wadzanai Samaneka; Javier Valencia; Karin Klingman; Beverly Allston-Smith; Katharine Cooper-Arnold; Patrice Desvigne-Nickens; Michael T Lu; Kathleen V Fitch; Udo Hoffman; Steven K Grinspoon; Pamela S Douglas; Sara E Looby
Journal:  J Infect Dis       Date:  2020-07-09       Impact factor: 7.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.